Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Nov 27 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.87 Insider Own42.47% Shs Outstand141.35M Perf Week34.58%
Market Cap224.55M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float89.71M Perf Month-25.00%
Income-116.92M PEG- EPS next Q-0.33 Inst Own18.46% Short Float / Ratio5.43% / 5.09 Perf Quarter-51.84%
Sales33.28M P/S6.75 EPS this Y- Inst Trans-11.91% Short Interest4.88M Perf Half Y-77.03%
Book/sh-1.73 P/B- EPS next Y- ROA-128.49% Target Price6.92 Perf Year-70.00%
Cash/sh0.01 P/C115.16 EPS next 5Y- ROE-163.31% 52W Range0.90 - 16.90 Perf YTD-63.91%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-91.48% Beta0.35
Dividend %- Quick Ratio0.09 Sales past 5Y10.72% Gross Margin67.46% 52W Low59.98% ATR0.19
Employees90 Current Ratio0.11 Sales Q/Q- Oper. Margin-449.43% RSI (14)50.21 Volatility20.48% 12.71%
OptionableYes Debt/Eq- EPS Q/Q-2441.00% Profit Margin-351.31% Rel Volume2.12 Prev Close1.27
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume958.50K Price1.44
Recom1.00 SMA202.98% SMA50-9.79% SMA200-73.49% Volume2,035,582 Change13.39%
Date Action Analyst Rating Change Price Target Change
Oct-16-23Initiated B. Riley Securities Buy $4
Oct-13-23Initiated B. Riley Securities Buy $4
Oct-09-23Initiated H.C. Wainwright Buy $12
Nov-27-23 09:00AM
Nov-22-23 09:00AM
Nov-21-23 09:00AM
Nov-17-23 09:00AM
Nov-15-23 09:00AM
09:00AM Loading…
Nov-02-23 09:00AM
Nov-01-23 09:00AM
Oct-27-23 03:38PM
Oct-26-23 06:12AM
Oct-09-23 02:55PM
Oct-07-23 07:27PM
Oct-04-23 12:59PM
Oct-03-23 09:00AM
09:00AM Loading…
Sep-27-23 09:00AM
Sep-25-23 09:00AM
Sep-22-23 11:38AM
Sep-21-23 04:05PM
Sep-14-23 09:00AM
Sep-13-23 09:00AM
Sep-12-23 05:34PM
Sep-11-23 09:00AM
Jul-27-23 09:00AM
Jul-21-23 05:53PM
Jul-20-23 09:00AM
Jul-13-23 09:00AM
Jul-05-23 09:00AM
09:00AM Loading…
Jun-16-23 09:00AM
Jun-15-23 09:03AM
Jun-01-23 12:28PM
May-31-23 03:16PM
May-22-23 09:00AM
May-14-23 03:00PM
May-05-23 06:08AM
May-04-23 09:00AM
Apr-28-23 02:42PM
Apr-27-23 07:26AM
Apr-25-23 07:30PM
Apr-17-23 09:00AM
Apr-14-23 06:32PM
Apr-13-23 12:25PM
Apr-05-23 05:27PM
Apr-04-23 01:49PM
Mar-27-23 09:00AM
Mar-21-23 09:00AM
Mar-08-23 10:13AM
Feb-27-23 09:00AM
Feb-18-23 08:37PM
Feb-17-23 03:47PM
Feb-16-23 02:40PM
Feb-13-23 03:46PM
Feb-04-23 10:48PM
Feb-03-23 08:59PM
Feb-02-23 01:15PM
Jan-20-23 10:24AM
Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. Its products include ZTlido, a prescription lidocaine topical product approved by the FDA for the relief of neuropathic pain associated with PHN, which is a form of post-shingles nerve pain, and e GLOPERBA oral solutions, an FDA-approved prophylactic treatment for painful gout flares in adults. The company was founded on February 21, 2020 and is headquartered in Palo Alto, CA.